Section 174 & 174A · Brief · Pro level
Unamortized Section 174 balances in M&A: stock deals, asset deals, and what diligence should ask
In a stock acquisition, the target's unamortized Section 174 balances survive and keep amortizing on their original schedule — a Section 381 carryover in a tax-free deal, simple continuity in a taxable one. In an asset deal, the balances stay behind with the seller, and the buyer takes cost basis in what it bought instead.
When a company that capitalized research costs under the TCJA-era Section 174 is bought, the unamortized balance goes wherever the corporation goes. In a stock deal the balance survives inside the target and keeps amortizing on its original clock; nothing about the purchase accelerates, steps up, or erases it. In an asset deal the balance stays behind — it is the seller's attribute, recovered under the seller's method — and the buyer starts fresh with cost basis in the assets it actually acquired. The distinction matters most for foreign research, which remains on 15-year amortization under Section 174 even after the OBBBA restored domestic expensing through Section 174A.
Stock deals: continuity, with a Section 381 label in reorganizations
A taxable stock purchase changes the target's ownership, not its tax attributes. The target's remaining domestic 2022–2024 capitalized amounts — including any OBBBA catch-up election to deduct them over one or two years — and its 15-year foreign research balances continue exactly as scheduled. A Section 338(h)(10) or 336(e) election converts the deal to a deemed asset sale, in which case the asset-deal analysis below controls instead.
In a tax-free reorganization or Section 332 liquidation, Section 381 does the same work formally: the acquiring corporation succeeds to the distributor's or transferor's accounting methods and inherits the amortization schedule as a Section 381(c) item. The acquirer steps into the target's shoes mid-schedule; it does not restart the recovery period. If acquirer and target used inconsistent 174-era methods, the post-combination method conformity rules can force a Form 3115 — see how method changes work.
Two attribute overlays deserve attention. First, the target's 174-driven NOLs travel with the stock and hit the Section 382 limitation on an ownership change — capitalization-era losses were large in software targets, and 382 can slow their use badly. Second, unused research credits carry over under Section 381(c)(24) but face their own 383 limitation.
Asset deals: the balance stays home
An asset sale transfers assets, not methods. The seller's unamortized 174 balance is not among the assets — under the TCJA-era statute, no deduction was allowed on disposition, retirement, or abandonment of the underlying property, so the seller generally continues amortizing its remaining balance after closing rather than deducting it against the sale (the same rule that governs abandoned projects). The sale proceeds are ordinary purchase price for the IP and other assets; the buyer allocates cost basis under Section 1060 and recovers acquired technology and workforce intangibles under Section 197 over 15 years — not under Section 174 at all, because acquiring finished research is not performing research.
The two sides of the same deal recover very different amounts on different clocks:
| Deal form | Seller's 174 balance | Buyer's recovery |
|---|---|---|
| Stock (taxable) | Survives inside target, original schedule | None — no basis step-up in target assets |
| Stock (tax-free reorg / 332) | Carries to acquirer under §381 | Inherits target's schedule mid-stream |
| Asset (or deemed asset: §338(h)(10), 336(e)) | Stays with seller; continues amortizing | §1060 allocation; §197 15-year on acquired intangibles |
Purchase accounting versus tax, and the diligence list
For financial reporting, most capitalized 174 costs were expensed as incurred under ASC 730 — the "asset" exists only as a deferred tax asset on the balance sheet, as covered in 174 and the financial statements. In purchase accounting the buyer separately fair-values developed technology, which bears no relationship to the tax balance. Diligence teams reading only the financials will either miss the balance or double-count it.
The stakes are asymmetric. In a stock deal, an unmodeled 174 balance is future deductions the buyer paid nothing for — or, if foreign, a 15-year drag the model missed. In an asset deal, a seller expecting to net the balance against gain will be disappointed. Price accordingly.
Frequently asked questions
- What happens to a target's unamortized Section 174 costs in a stock acquisition?
- They stay with the target corporation and continue amortizing on their original schedule — 15 years for foreign research, and the remaining domestic 2022–2024 balances on whatever catch-up or amortization track the target chose after the OBBBA. A stock purchase does not step up or eliminate the balances; in a tax-free reorganization, Section 381 carries the method and the balances to the acquirer.
- Does the buyer in an asset deal inherit the seller's Section 174 amortization?
- No. Unamortized Section 174 balances are the seller's tax attribute, not a transferable asset. The seller generally recovers its remaining balance under its own method (the disposition does not accelerate it into the year of sale under the TCJA-era rule), while the buyer capitalizes its purchase price into the acquired IP and other assets under normal cost-basis rules.
- Why do Section 174 balances create purchase-accounting confusion?
- Because book and tax diverge. For financial reporting, capitalized 174 costs usually exist only as a deferred tax asset, not a booked intangible; in purchase accounting the buyer fair-values the target's technology separately. Diligence teams that read the balance off the financials will miss it — the balance lives on the tax return, in the amortization schedules supporting Part VI of Form 4562.